07/2025. cDC1, Immunity, and Atherosclerosis
Published in Circulation Research, this study identifies conventional type 1 dendritic cells (cDC1s) as key regulators of local immunity in atherosclerosis.
The authors demonstrate that cDC1s drive atherosclerotic plaque progression through activation of adaptive immunity.
Using murine models with gain- and loss-of-function approaches, the study shows that cDC1s promote proatherogenic CD4⁺ Th1 and CD8⁺ IFN-γ⁺ T-cell responses. STING signaling in cDC1s is essential for this effect. As a therapeutic proof of concept, cDC1-targeted nanoparticles loaded with dexamethasone reduce atherosclerosis without impairing antiviral immunity.
This research was led by investigators from the National Center for Cardiovascular Research Carlos III (CNIC), Spain, with the collaboration of INMUNOTEK.










